Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Sponsor: Diakonhjemmet Hospital
Summary
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.
Official title: Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study
Key Details
Gender
All
Age Range
25 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
160
Start Date
2025-01-01
Completion Date
2028-12
Last Updated
2025-08-24
Healthy Volunteers
No
Interventions
Glucocorticoid Effect
Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
Locations (2)
Vestre Viken HF, Drammen
Drammen, Norway
Diakonhjemmet hospital
Oslo, Norway